European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

Journal of the Neurological Sciences

Volumn 143, Issue 1-2, 1996, Pages 1-13

  Diener, H C ^a   Cunha, L ^a   Forbes, C ^a   Sivenius, J ^a   Smets, P ^a   Lowenthal, A ^a  

^a NONE   (Belgium)

Author keywords

Acetylsalicylic acid; Dipyridamole; Secondary prevention; Stroke; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; ASPIRIN; CEREBROVASCULAR DISORDERS; DEMOGRAPHY; DIPYRIDAMOLE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; PATIENT COMPLIANCE; PLACEBOS; PLATELET AGGREGATION INHIBITORS; SURVIVAL ANALYSIS;

EID: 0030297319     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(96)00308-5     Document Type: Article

References (22)

1. Alheid U., Reichwehr I., Foerstermann U. Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP. Eur J Pharmacol. 164:1989;103-110.
2. American-Canadian Co-operative Study Group Persantin aspirin trial in cerebral ischemia. II: Endpoint results Stroke. 16:1983;406-415.
3. Anti-platelet Trialists' Collaboration Secondary prevention of vascular diseases by prolonged antiplatelet treatment. Br Med J. 296:1988;320-331.
4. Anti-platelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients Br Med J. 308:1994;81-106.
5. Anti-platelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy Br Med J. 308:1994;159-168.
6. Anti-platelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy. III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients Br Med J. 308:1994;235-246.
7. Bertrand-Hardy J.M., Cunha L., Forbes C., Hoeven C., Hogenhuis L., Lowenthal A.et al. European Stroke Prevention Study 2: Baseline data. J Neurol Sci. 131((Suppl.)):1995;1-58.
8. Bonita R. Epidemiology of stroke. Lancet. 339:1992;342-344.
9. Bousser M.G., Eschwege E, Hagenah M, Lefaucconnier JM, Thibult N, Touboul D, Touboul PJ `AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 14:1983;5-14.
10. EAFT Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-62.
11. ESPS Group. The European Stroke Prevention Study (ESPS): Principal endpoints. Lancet 1987; ii: 1351-4.
12. ESPS Group. European Stroke Prevention Study. Stroke 1990; 21: 1122-30.
13. Fields W.S., Lemak N.A., Frankowski R.F., Hardy R.J. Controlled trial of aspirin in cerebral ischemia. Stroke. 8:1977;301-316.
14. Gent, M., Easton, J.D., Hachinski, V.C., Panak, E., Sicurella, J., Blakely JA, et al, and the CATS Group. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; ii: 1215-1220.
15. Hass W.K., Easton J.D., Adams H.P. Jr., Pryse-Philips W., Molony B.A., Anderson Set al. Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 321:1989;501-507.
16. Miller, R.G. Survival Analysis. New York: J Wiley and Sons, 1981.
17. Müller T.H., Su C.A.P.F., Weisenberger H., Brickl R., Nehmiz G., Eisert W.G. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmac. 30:1990;179-186.
18. Patrono C., Roth G.J. Aspirin in ischaemic cerebrovascular disease. How strong is the case for a different dosing regimen? Stroke. 27:1996;756-760.
19. Pocock, J., Clinical Trials. Chichester: J Wiley and Sons, 1983.
20. SALT Collaborative Group Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 338:1991;1345-1349.
21. UK-TIA Study Group The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 54:1991;1044-1054.
22. Van Swieten J.C., Koudstaal P.J., Visser M.C., Schouten H.J.A., Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 19:1988;604-607.